HC Wainwright & Co. Reiterates Buy on Crescent Biopharma, Maintains $36 Price Target
10/19/2026
Impact: 70
Healthcare
HC Wainwright & Co. analyst Mitchell S. Kapoor has reiterated a Buy rating on Crescent Biopharma (NASDAQ: CBIO) and maintained a price target of $36 for the stock.
AI summary, not financial advice
Share: